-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Serum bilium is negatively associated with cardiovascular risk.
Azanave is an HIV protease inhibitor that competes against bilirin binding, a trait that provides an opportunity to assess whether selectively increasing bilirin has a heart-protective effect.
A recent study published in JAHA, an authoritative journal in the field of cardiovascular disease, researchers sought to make it clear whether patients who received azanave had a lower risk of cardiovascular disease than those who received Trinave, an HIV protease inhibitor that does not increase serum bililubin.
this is a retrospective queue study of 1,020 HIV patients.
the study's main outcome occurred at the time of myocardial infarction or ischemic stroke.
the average follow-up time was 6.6±3.4 years, of which 516 were treated with Azanave and 504 by Tyrinaway.
total bililin levels (1.7 vs. 0.4 mg/dL;P<0.001) were significantly higher in Azanave therapists, and the average ischemia time was longer (10.2 vs. 9.4 years; P.lt;0.001).
in Cox regression analysis, Azanave therapy (risk ratio is 0.38; 95% CI is 0.21-0.71; P is 0.00) 2) and serum bilirin (HR is 0.60; 95% CI is 0.41-0.89; P=0.011) are independently associated with a lower risk of ishemia events.
it is worth noting that when Azanave and bilibin were included in the Cox regression model, the correlation between Azanave therapy and a lower risk of ischemia events was not significant (HR was 0.55; 95% CI was 0.24-1.29; P=0.169).
risk of developing new cardiovascular disease was also significantly reduced in patients using Azanave (HR 0.53; 95% CI was 0.33-0.86; P=0.010), and the average time of death was longer (12.2 years vs. 10.8 years; P.lt;0.001).
thus, the risk of cardiovascular disease in HIV patients treated with Azanave appears to be mediated by serum bilibin compared to patients treated with Trinave.
.